FDA Adverse Event Injury Summary report: N

ESSURE

MDR report key: 10372493 · Received August 6, 2020

Report

Report Number
2951250-2020-12711
Event Type
Injury
Date Received
August 6, 2020
Report Date
August 10, 2020
Manufacturer
BAYER PHARMA AG
Product Code
HHS
UDI-DI
10888853003051
PMA / PMN Number
P020014
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
FR
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 0

THIS LITERATURE CASE DESCRIBES THE OCCURRENCE OF PRURITUS ('ITCHING') IN AN ADULT FEMALE PATIENT WHO HAD ESSURE INSERTED. LITERATURE REFERENCE: PARANTA F, BOSTA M, NOHUZB N, PROSTA J, CERRUTOB E, MORET S, MAURIN J, GAUTIER C, POTENTIAL RELEASE OF TOXIC METAL ELEMENTS FROM ESSURE DEVICE IN SYMPTOMATIC PATIENTS: FIRST RESULTS OF THE FRENCH ABLIMCO COHORT, EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY 252, 2020. ON AN UNKNOWN DATE, THE PATIENT HAD ESSURE INSERTED. ON AN UNKNOWN DATE, THE PATIENT EXPERIENCED PRURITUS (SERIOUSNESS CRITERIA MEDICALLY SIGNIFICANT AND INTERVENTION REQUIRED). THE PATIENT WAS TREATED WITH SURGERY (LAPAROSCOPIC ESSURE REMOVAL). ESSURE WAS REMOVED. AT THE TIME OF THE REPORT, THE PRURITUS OUTCOME WAS UNKNOWN. THE REPORTER CONSIDERED PRURITUS TO BE RELATED TO ESSURE. QUALITY-SAFETY EVALUATION OF PTC: UNABLE TO CONFIRM COMPLAINT . OBJECTIVE: MANY PATIENTS WITH ESSURE DEVICES REQUEST THE REMOVAL OF THESE IMPLANTS DUE TO PERSISTENT ADVERSE EFFECTS. THE PATHOPHYSIOLOGY REMAINS UNKNOWN, BUT A CORROSION OF THE IMPLANTS IN THE IN-VIVO ENVIRONMENT LEADING TO METAL ION RELEASE MAY BE SUSPECTED. THE IMPLANTS CONSIST OF POLYESTER FIBERS, NICKEL-TITANIUM ALLOY AND OTHER METALS INCLUDING CHROMIUM. THE PURPOSE OF THIS STUDY IS TO DELIVER THE FIRST RESULTS ON THE CONCENTRATIONS OF NICKEL AND CHROMIUM (TWO POTENTIAL TOXIC METAL ELEMENTS) IN PERITONEAL FLUID AND IN THE FALLOPIAN TUBE TISSUE DURING LAPAROSCOPIC REMOVAL OF ESSURE. STUDY DESIGN: IN THIS PROSPECTIVE OBSERVATIONAL STUDY CONDUCTED IN A FRENCH ACADEMIC RESEARCH HOSPITAL, NICKEL AND CHROMIUM CONCENTRATIONS WERE DETERMINED IN THE FALLOPIAN TUBE TISSUE AND PERITONEAL LIQUID FROM SYMPTOMATIC PATIENTS WITH ESSURE BY INDUCTIVELY COUPLED PLASMA MASS SPECTROMETRY (ICP-MS) ANALYSIS IN A PERKINELMER NEXION 350. RESULTS: SIGNIFICANT METAL ELEMENT CONCENTRATIONS WERE SHOWED IN THE PERITONEAL FLUID. THERE WAS ALSO A DIFFERENTIAL CONCENTRATION IN THE FALLOPIAN TUBE TISSUE WITH HIGHER CONCENTRATION CLOSE TO THE IMPLANT THAN LOWER AT A DISTANCE FROM THIS IMPLANT. THERE WAS A CORRELATION BETWEEN THE CONCENTRATIONS OF THE TWO METALS. CONCLUSION: THE PRESENCE OF NICKEL AND CHROMIUM IN THE FALLOPIAN TUBE TISSUE AND THE PERITONEAL FLUID RAISES THE QUESTION OF A POSSIBLE RELATIONSHIP BETWEEN THE SYMPTOMS ATTRIBUTED TO ESSURE IMPLANTS AND THE DISSEMINATION OF POTENTIAL TOXIC METALS DUE TO GALVANIC CORROSION OF THE DEVICES. THIS REPORT REFERS TO A SINGLE PATIENT IN TABLE 1 WHO EXPERIENCED ITCHING MOST RECENT FOLLOW-UP INFORMATION INCORPORATED ABOVE INCLUDES: ON 6-AUG-2020: QUALITY-SAFETY EVALUATION OF PTC. ON 6-AUG-2020: HA NUMBER RECEIVED - R2011982. BASED ON THE AVAILABLE INFORMATION, A REVIEW OF OUR COMPLAINT RECORDS AND OTHER RELEVANT DATA WAS CONDUCTED; ANY NEW AND REPORTABLE INFORMATION THAT BECOMES AVAILABLE FROM OUR INVESTIGATION WILL BE PROVIDED IN A SUPPLEMENTARY REPORT.

Description of Event or Problem · 1

THIS LITERATURE CASE DESCRIBES THE OCCURRENCE OF PRURITUS ('ITCHING') IN AN ADULT FEMALE PATIENT WHO HAD ESSURE INSERTED. LITERATURE REFERENCE: PARANTA F, BOSTA M, NOHUZB N, PROSTA J, CERRUTOB E, MORET S, MAURIN J, GAUTIER C, POTENTIAL RELEASE OF TOXIC METAL ELEMENTS FROM ESSURE DEVICE IN SYMPTOMATIC PATIENTS: FIRST RESULTS OF THE FRENCH ABLIMCO COHORT, EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY 252, 2020. ON AN UNKNOWN DATE, THE PATIENT HAD ESSURE INSERTED. ON AN UNKNOWN DATE, THE PATIENT EXPERIENCED PRURITUS (SERIOUSNESS CRITERIA MEDICALLY SIGNIFICANT AND INTERVENTION REQUIRED). THE PATIENT WAS TREATED WITH SURGERY (LAPAROSCOPIC ESSURE REMOVAL). ESSURE WAS REMOVED. AT THE TIME OF THE REPORT, THE PRURITUS OUTCOME WAS UNKNOWN. THE REPORTER CONSIDERED PRURITUS TO BE RELATED TO ESSURE. OBJECTIVE: MANY PATIENTS WITH ESSURE DEVICES REQUEST THE REMOVAL OF THESE IMPLANTS DUE TO PERSISTENT ADVERSE EFFECTS. THE PATHOPHYSIOLOGY REMAINS UNKNOWN, BUT A CORROSION OF THE IMPLANTS IN THE IN-VIVO ENVIRONMENT LEADING TO METAL ION RELEASE MAY BE SUSPECTED. THE IMPLANTS CONSIST OF POLYESTER FIBERS, NICKEL-TITANIUM ALLOY AND OTHER METALS INCLUDING CHROMIUM. THE PURPOSE OF THIS STUDY IS TO DELIVER THE FIRST RESULTS ON THE CONCENTRATIONS OF NICKEL AND CHROMIUM (TWO POTENTIAL TOXIC METAL ELEMENTS) IN PERITONEAL FLUID AND IN THE FALLOPIAN TUBE TISSUE DURING LAPAROSCOPIC REMOVAL OF ESSURE. STUDY DESIGN: IN THIS PROSPECTIVE OBSERVATIONAL STUDY CONDUCTED IN A FRENCH ACADEMIC RESEARCH HOSPITAL, NICKEL AND CHROMIUM CONCENTRATIONS WERE DETERMINED IN THE FALLOPIAN TUBE TISSUE AND PERITONEAL LIQUID FROM SYMPTOMATIC PATIENTS WITH ESSURE BY INDUCTIVELY COUPLED PLASMA MASS SPECTROMETRY (ICP-MS) ANALYSIS IN A PERKINELMER NEXION 350. RESULTS: SIGNIFICANT METAL ELEMENT CONCENTRATIONS WERE SHOWED IN THE PERITONEAL FLUID. THERE WAS ALSO A DIFFERENTIAL CONCENTRATION IN THE FALLOPIAN TUBE TISSUE WITH HIGHER CONCENTRATION CLOSE TO THE IMPLANT THAN LOWER AT A DISTANCE FROM THIS IMPLANT. THERE WAS A CORRELATION BETWEEN THE CONCENTRATIONS OF THE TWO METALS. CONCLUSION: THE PRESENCE OF NICKEL AND CHROMIUM IN THE FALLOPIAN TUBE TISSUE AND THE PERITONEAL FLUID RAISES THE QUESTION OF A POSSIBLE RELATIONSHIP BETWEEN THE SYMPTOMS ATTRIBUTED TO ESSURE IMPLANTS AND THE DISSEMINATION OF POTENTIAL TOXIC METALS DUE TO GALVANIC CORROSION OF THE DEVICES. THIS REPORT REFERS TO A SINGLE PATIENT IN TABLE 1 WHO EXPERIENCED ITCHING. BASED ON THE AVAILABLE INFORMATION, A REVIEW OF OUR COMPLAINT RECORDS AND OTHER RELEVANT DATA WILL BE CONDUCTED; ANY NEW AND REPORTABLE INFORMATION THAT BECOMES AVAILABLE FROM OUR INVESTIGATION WILL BE PROVIDED IN A SUPPLEMENTARY REPORT.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
840126 ESSURE TRANSCERVICAL CONTRACEPTIVE TUBAL OCCLUSION DEVICE HHS BAYER PHARMA AG ESS305 10888853003051

Patients

Seq Age Sex Outcome Treatment
1 Other| R